Matches in Nanopublications for { ?s ?p "[Crizotinib, an oral ALK inhibitor, has proved to provide dramatic clinical benefit in patients with NSCLC harboring ALK rearrangements.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP8474.RARebbXS8QQ58PnrX0CrUK-wtdLl34mLaOfAkJpxhzUEs130_assertion description "[Crizotinib, an oral ALK inhibitor, has proved to provide dramatic clinical benefit in patients with NSCLC harboring ALK rearrangements.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP8474.RARebbXS8QQ58PnrX0CrUK-wtdLl34mLaOfAkJpxhzUEs130_provenance.
- NP8490.RADFBQi7cVWx_4j9lyvHnacVVWOCsYbIPNc8lbGTGY6yQ130_assertion description "[Crizotinib, an oral ALK inhibitor, has proved to provide dramatic clinical benefit in patients with NSCLC harboring ALK rearrangements.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP8490.RADFBQi7cVWx_4j9lyvHnacVVWOCsYbIPNc8lbGTGY6yQ130_provenance.
- assertion description "[Crizotinib, an oral ALK inhibitor, has proved to provide dramatic clinical benefit in patients with NSCLC harboring ALK rearrangements.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP8461.RAP_kd7VjNBwNAkAKtKtL8cvqx3Q1-WgPbicRbXdDDRqw130_assertion description "[Crizotinib, an oral ALK inhibitor, has proved to provide dramatic clinical benefit in patients with NSCLC harboring ALK rearrangements.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP8461.RAP_kd7VjNBwNAkAKtKtL8cvqx3Q1-WgPbicRbXdDDRqw130_provenance.
- NP8480.RAGvOw1IvZJgNPdrQUsfLBUQExcLgbgQ-Oc8yiZTZyiyM130_assertion description "[Crizotinib, an oral ALK inhibitor, has proved to provide dramatic clinical benefit in patients with NSCLC harboring ALK rearrangements.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP8480.RAGvOw1IvZJgNPdrQUsfLBUQExcLgbgQ-Oc8yiZTZyiyM130_provenance.
- NP6718.RAbVH457b-LkpJWRMgTw7ueS7pj6MBG5QtMY95W0zUhuQ130_assertion description "[Crizotinib, an oral ALK inhibitor, has proved to provide dramatic clinical benefit in patients with NSCLC harboring ALK rearrangements.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP6718.RAbVH457b-LkpJWRMgTw7ueS7pj6MBG5QtMY95W0zUhuQ130_provenance.